# Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)

> **NCT06923826** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 32 (estimated)

## Conditions studied

- Salivary Gland Cancer
- Thyroid Cancer

## Interventions

- **DRUG:** Sacituzumab govitecan

## Key facts

- **NCT ID:** NCT06923826
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2025-07-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923826, "Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06923826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*